Phase II study of the combination carboplatin and paclitaxel in patients with ovarian cancer
Authors:
- L. J. C. van WarmerdamLWL. J. C. van Warmerdam
- T. J. HelmerhorstTHT. J. Helmerhorst
- M. C. W. SchaefersMSM. C. W. Schaefers
- I. H. BeijnenIBI. H. Beijnen
- S. RodenhuisSRS. Rodenhuis
Open Access
- 1 April 1997
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 8 (4) , 351-354
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.Journal of Clinical Oncology, 1997
- Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group.Journal of Clinical Oncology, 1996
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Taxanes: A New Class of Antitumor AgentsCancer Investigation, 1995
- Chemotherapy in Advanced Ovarian Carcinoma: Current Standards of Care Based on Randomized TrialsGynecologic Oncology, 1994
- PaclitaxelDrugs, 1994
- Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting.Journal of Clinical Oncology, 1993
- Carboplatin versus cisplatinAnnals of Oncology, 1993
- Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer.Journal of Clinical Oncology, 1992
- CarboplatinDrugs, 1989